Day 3 Program

Poster Spotlight 6: Tools for Predicting Response and Outcomes with Neoadjuvant Therapy

Day 3: December 11, 2025

7:00 AM–8:30 AM CST

301 ABC

Session Details

The text of the abstracts will be posted on Monday, November 24.

Moderator

Antonio Wolff, Johns Hopkins University, Baltimore, MD

PD6-01

Mid-treatment MRI response as a surrogate for breast pCR in TNBC: Implications for neoadjuvant chemotherapy de-escalation

Soong June Bae, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

PD6-02

Impact of early magnetic resonance imaging assesment on prediction of pathologic complete response and long-term outcomes in triple-negative breast cancer treated with neoadjuvant pembrolizumab

Alicia Carrasco Navas, Hospital Universitario Parc Taulí, Sabadell, Spain

PD6-03

Validation of MRI predictive models for treatment optimization in the I-SPY 2 TRIAL

Wen Li, University of California, San Francisco, San Francisco, CA

PD6-04

Tumor Boundary and Shape Features are Predictive of Recurrence in Triple Negative Breast Cancer (TNBC) Patients

Soumya Ghose, GE HealthCare, Schenectady, NY

PD6-05

Discussant: Imaging

David A Mankoff, University of Pennsylvania, Philadelphia, PA

PD6-06

Angiogenesis contributes to chemoimmunotherapy resistance in immune-high and immune-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial

Priyanka Sharma, University of Kansas Medical Center, Kansas City, KS

PD6-07

Ctdna dynamics is most predictive of response in treatment-sensitive response-predictive subtypes of breast cancer: results from the I-SPY2 trial

Mark Jesus Magbanua, University of California San Francisco, San Francisco, CA

PD6-08

Early dynamics of tumor microenvironment in triple negative or ER-low breast cancer: updated analyses from window of opportunity (WOO) MEDIOLA trial of olaparib and durvalumab

Jiwon Koh, Seoul National University Hospital, Seoul, Korea, Republic of

PD6-09

Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL

Douglas Yee, University of Minnesota, Minneapolis, MN

PD6-10

Omission of Axillary Dissection in ypN1mi Breast Cancer Patients after Neoadjuvant Chemotherapy: Preliminary Results from the NEONOD2 Trial

Damiano Gentile, IRCCS Humanitas Research Hospital, Milan, Italy

PD6-11

Discussant: Molecular

Sangeetha Meda Reddy, University of Texas Southwestern Medical Center, Dallas, TX